Navigation Links
Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
Date:2/8/2008

Clinical Experts To Oversee Phase 3 Program of CGT-2168

MENLO PARK, Calif., Feb. 8 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc., today named a distinguished international panel of medical experts to serve on the Scientific Steering Committee charged with overseeing COGENT, the company's global Phase 3 clinical trial program for its novel combination antiplatelet product CGT-2168.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The panel includes experts in the fields of cardiology, gastroenterology and clinical investigation. "We are extremely pleased that these accomplished clinical scientists will advise us on the COGENT program. Their participation will help ensure its scientific success," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

Members of the COGENT Scientific Steering Committee are:

-- Dr. Deepak Bhatt, Associate Director, Cardiovascular Coordinating

Center, Cleveland Clinic, Cleveland, Ohio

-- Dr. Marc Cohen, Director of the Division of Cardiology, Newark Beth

Israel Medical Center, Newark, New Jersey

-- Dr. Byron Cryer, John C. Vanatta III Professor of Medicine and

Associate Dean for Minority Affairs, Southwestern Medical School,

Dallas, Texas

-- Dr. Angel Lanas, Service of Gastroenterology, University Hospital,

Zaragoza, Spain

-- Dr. Thomas Schnitzer, Professor of Medicine, Division of Rheumatology,

Northwestern University Feinberg School of Medicine, Chicago, Illinois

The Scientific Steering Committee will be responsible for providing scientific and clinical oversight and advice to ensure the data that emerge from the COGENT program are of the highest quality and that the highest level of scientific conduct is maintained.

The ongoing COGENT program will evaluate the efficacy and safety of Cogentus's lead product, CGT-2168, which combines the antiplatelet medicine clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole).

While antiplatelet therapy has been shown to be effective in preventing major cardiovascular events, it is associated with significant gastrointestinal side effects including bleeding, which can interrupt treatment, may require hospitalization or in some cases even result in death. Bleeding from the use of the antiplatelet drugs aspirin and clopidogrel has been shown respectively to be the third and fourth most common causes of U.S. emergency room visits by older adults experiencing adverse drug events.

"It is critical that patients are able to remain on treatment," Dr. Goldsmith said. A new analysis published in this week's Journal of the American Medical Association showed that patients with acute coronary syndrome who stopped taking Plavix nearly doubled their risk of heart attack or death within the first 90 days following the end of treatment.

CGT-2168 is designed to maintain full protective cardiovascular benefits while reducing the potentially serious gastrointestinal side effects commonly associated with antiplatelet therapy. Early results with CGT-2168 show excellent absorption and metabolism of clopidogrel that are unaffected by the delayed-release omeprazole within this combination product. Cogentus believes these findings suggest the novel formulation avoids a drug-drug interaction that has been reported when the individual marketed drugs are co-administered.

"It is important for patients to receive the full cardiovascular effect of dual antiplatelet therapy while reducing gastrointestinal side effects," said Steering Committee member Dr. Marc Cohen. "The COGENT program is evaluating whether CGT-2168 will maintain the cardiovascular benefits of treatment while minimizing bleeding."

"We believe CGT-2168 has the potential to offer an effective yet safer treatment option for the millions of patients who require antiplatelet therapy. With the help of the Scientific Steering Committee, we are committed to a thorough evaluation of the potentially significant benefits of this new medicine," Dr. Goldsmith said.

ABOUT COGENT

COGENT stands for the Clopidogrel and the Optimization of Gastrointestinal Events Trial. The program is expected to enroll more than 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America. The COGENT program is designed to measure the incidence of upper gastrointestinal bleeding and ulcers in patients who take CGT-2168 and aspirin compared with patients who take clopidogrel and aspirin. The vast majority of patients who take clopidogrel also take aspirin.

Physicians and patients interested in obtaining more information about COGENT should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... interactive publication where generations converge and explore the world from different perspectives. By ... Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... New York (PRWEB) , ... February 23, 2017 , ... ... evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is ... 30 clinical sites already enrolling children across the United States. , “There are ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) ... the nation’s largest healthcare systems recently invested $51 million to purchase and renovate ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 According to a ... (X-ray Imaging Digital, Analog), MRI (Closed, Open), Ultrasound, CT, ... Oncology), End User (Hospitals, Imaging Centers) - Global Forecast ... global market over the forecast period of 2016 to ... Billion by 2021, at a CAGR of 6.6% from ...
(Date:2/23/2017)... YORK , February 23, 2017 ... its report on the global market for intraoperative ... be presently valued at US$ 513.9 million. According ... will keep surging on the grounds of increasing ... in the field of diagnostic imaging for neurosurgeries. ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market is ... next decade to reach approximately $8.9 billion by 2025. ... the given segments on global as well as regional levels presented ...
Breaking Medicine Technology: